

# Consolidation nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiation for patients with NSCLC

August 8 2022

---

Following concurrent chemoradiation for unresectable stage III non-small cell lung cancer, both nivolumab alone and nivolumab and ipilimumab combined demonstrated improved 18-month progression-free survival compared with historical controls despite a shortened interval (6 months) of treatment. The research was presented today at the IASLC 2022 World Conference on Lung Cancer in Vienna.

[The PACIFIC trial](#) demonstrated that a year of consolidation PD-(L)1 inhibition following concurrent chemoradiation (CRT) for unresectable stage III NSCLC improves overall survival, but the optimal duration of consolidation immunotherapy in this setting is undefined.

Studies in metastatic NSCLC demonstrate that combination PD-(L)1/CTLA-4 inhibition improves overall survival compared to chemotherapy alone. This trial evaluated the use of combination nivolumab plus ipilimumab or nivolumab alone for up to six months in unresectable stage III NSCLC after concurrent chemoradiation.

Dr. Greg Durm, Indiana University Melvin and Bren Simon Cancer Center, Bloomington, Ind., and colleagues created a randomized phase II, multicenter trial of 105 patients with unresectable stage IIIA/IIIB NSCLC. All patients received concurrent chemoradiation and were then enrolled and randomized 1:1 to receive nivolumab 480mg IV q4wks (Arm A) for up to 24 weeks or [nivolumab](#) 3mg/kg IV q2 weeks and

ipilimumab 1mg/kg IV q6 weeks (Arm B) for up to 24 weeks. The primary endpoint is 18-month progression-free survival compared to historical controls of chemoradiation alone for arm A (30%) and chemoradiation followed by durvlumab for arm B (44%).

From September 2017 to April 2021, 105 pts were enrolled and randomized, 54 to N alone (A) and 51 to N + IPI (B). The baseline characteristics for arm A/B: [median age](#) (65/63), male (44.4%/56.9%), stage IIIA (55.6%/56.9%), stage IIIB (44.4%/43.1%), non-squamous (57.4%/54.9%), and squamous (42.6%/45.1%). The percentage of pts completing the full treatment was 70.4% in A and 56.9% in B (p=0.15). Median f/u was 24.5 and 24.1 months on A and B, respectively.

The 18- month progression-free survival was 62.3% on Arm A (p

Citation: Consolidation nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiation for patients with NSCLC (2022, August 8) retrieved 1 April 2023 from <https://medicalxpress.com/news/2022-08-nivolumab-ipilimumab-concurrent-chemoradiation-patients.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.